• Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

  • Known Financial Commitments (USD)

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)
  • Principle Investigator

  • Research Location

    United States of America, Americas
  • Lead Research Institution

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



Antigen is recombinant full-length S protein nanoparticles engineered in baculovirus and expressed in Sf9 insect cells; Adjuvant is saponin-based Matrix-M (raw material sourced from tree bark from source in Chile)Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Two structurally new Lindqvist hexaniobate-templated silver thiolate clusters.

Clinical features of patients with mutations in genes for nanophthalmos.

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.

Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.

Role of NaV1.7 in postganglionic sympathetic nerve function in human and guinea-pig arteries.

Gut-Directed Hypnotherapy May Pose Specific Challenges in Gender-Diverse Patients: A Review of 3 Patients.

Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data.

Misregulation of bromotyrosine compromises fertility in male Drosophila.

PSCK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis.